Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic ...

The shares of Tata Motors, which now represent the automaker's CV business, rose more than 5 percent on December 18 after JPMorgan and BofA Securities initiated coverage on the stock with bullish ...

Navigating the job market requires understanding the difference between a resume and a CV. A CV is a comprehensive academic and professional record, while a resume offers a concise snapshot of your ...

Tata Motors shares (Commercial Vehicles) were listed at ₹335 apiece on NSE, a premium of 28.48% to its discovered price of ₹260.75 per share.(Photo: AFP) Tata Motors Commercial Vehicles arm’s shares ...

Shares of Tata Motors Commercial Vehicles Ltd. listed at a premium of 28% to its implied value, as investors cheered the standalone listing of India's largest truck-and-bus maker. That, in effect, ...

The shares of Tata Motors' commercial vehicle business were listed at Rs 335 apiece on the NSE on November 12, marking a premium of more than 28.5 percent from the discovered price. This officially ...

Tata Motors Commercial Vehicles will list as Tata Motors Ltd. on India's stock exchanges on 12 November, in completion of a demerger that split the PV and CV units of India's largest automaker. A Tata ...

Tata Motors demerger, effective from October 1, 2025, has officially split the company into two listed entities — Tata Motors Passenger Vehicles Ltd, which houses Jaguar & Land Rover (JLR) and ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

The fifth week of the fantasy football season is here, and with it come the first batch of byes. In fact, nine of the next 10 weeks on the league’s slate will include at least two teams on a bye. This ...

Tom Lane does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...